Compounds › Repair and tissue

KPV

Anti-inflammatory tripeptide, fragment of α-MSH

Not approvedRepair and tissue

AI-generated illustration. Not data, and not an image from a study.

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Summary

Short peptide studied mainly in laboratory and animal research. It is the terminal fragment of α-MSH and the component that sets the KLOW blend apart from GLOW. Interest lies in intestinal and skin inflammation. It comes in 5 mg and 10 mg vials.

Quick reference

Route: Subcutaneous and topical.
Vials: 5 mg and 10 mg lyophilized.
Origin: Terminal fragment of α-MSH; it is what sets KLOW apart from GLOW.
Status: Not approved. Laboratory and animal research.

KPV Peptide Dosage Chart

Research calculation	5 mg vial + 1 mL	10 mg vial + 2 mL	U-100 syringe units
200 mcg	0.04 mL	0.04 mL	4 units
300 mcg	0.06 mL	0.06 mL	6 units
400 mcg	0.08 mL	0.08 mL	8 units
500 mcg	0.10 mL	0.10 mL	10 units

KPV 10 mg Dosage Chart

Research calculation	Volume	U-100 units	Approximate calculations per vial
200 mcg	0.04 mL	4 units	50
300 mcg	0.06 mL	6 units	33
400 mcg	0.08 mL	8 units	25
500 mcg	0.10 mL	10 units	20

KPV 5 mg Dosage Chart

Research calculation	Volume	U-100 units	Approximate calculations per vial
200 mcg	0.04 mL	4 units	25
300 mcg	0.06 mL	6 units	16 full calculations, with some remaining
400 mcg	0.08 mL	8 units	12 full calculations, with some remaining
500 mcg	0.10 mL	10 units	10

KPV Protocol: Daily Dose, Frequency, and Schedule

Route	Commonly discussed research range	Frequency discussed in community protocols	Evidence label
SubQ	200–500 mcg	Generally 1×/day	Community-reported practice; not clinically established
Oral	200–500 mcg	Generally 1× or 2×/day	Community-reported practice; not clinically established
Topical	Formulation-specific	Generally 1× or 2×/day	Formulation and clinic practice vary

Reconstitution formulas

Vial size	BAC water added	Concentration	200 mcg	300 mcg	500 mcg
5 mg	1 mL	5,000 mcg/mL	0.04 mL (4 units)	0.06 mL (6 units)	0.10 mL (10 units)
5 mg	2 mL	2,500 mcg/mL	0.08 mL (8 units)	0.12 mL (12 units)	0.20 mL (20 units)
10 mg	2 mL	5,000 mcg/mL	0.04 mL (4 units)	0.06 mL (6 units)	0.10 mL (10 units)
10 mg	3 mL	3,333 mcg/mL	0.06 mL (6 units)	0.09 mL (9 units)	0.15 mL (15 units)
10 mg	5 mL	2,000 mcg/mL	0.10 mL (10 units)	0.15 mL (15 units)	0.25 mL (25 units)

KPV vs BPC-157 vs alpha-MSH

Feature	KPV	BPC-157	alpha-MSH (full-length)
Origin	C-terminal tripeptide of alpha-MSH	Synthetic 15-aa gastric-protein fragment	Endogenous 13-aa melanocortin hormone
Primary mechanism	PepT1 uptake; NF-kB inhibition	Angiogenesis; tissue-protective signaling	Melanocortin-receptor activation
Primary use model	Inflammation control; gut-barrier support	Structural tissue repair	Pigmentation; melanocortin signaling
Oral viability	Yes (PepT1)	Yes	Limited
Pigmentation effects	No	No	Yes
Clinical evidence	Preclinical only	Limited human + broad preclinical	Extensive hormonal research

KPV Cycle Length Chart

Framework	Reported active period	Reported break	Evidence level
Short cycle	4 weeks	2–4 weeks	Common community reference; no controlled human trial
Standard community range	6–8 weeks	2–4 weeks	Frequently discussed; not clinically established
Extended cycle	12 weeks	About 4 weeks or longer	Reported extension with limited long-term evidence
Long extension	Up to 16 weeks	4–8 weeks	Anecdotal; no KPV trial validates this duration

Community KPV Cycles vs. Research Study Durations

Source	Example duration	What was studied	What it tells us
Community protocols	4–8 weeks	Oral or SubQ research frameworks	Shows a commonly discussed schedule, not a validated cycle
Extended community protocols	8–12 weeks	Longer research planning	Documents an extension, not proof that longer is better
Dalmasso et al. (2008)	48 hours to 8 days	Mouse colitis models and PepT1 transport	Supports short preclinical research, not a human cycle
Kannengiesser et al. (2008)	Days in murine colitis models	KPV in DSS and transfer-colitis models	Shows animal anti-inflammatory research only
Xiao et al. (2017)	Daily treatment in a short DSS model	Oral KPV-loaded nanoparticles in mice	Supports a delivery-system experiment, not free-KPV cycle guidance
Dalmasso et al. (2016)	Repeated DSS periods with recovery windows	Colitis-associated cancer model in mice	Shows a longer animal design, not a continuous human protocol

What About a 6- to 8-Week KPV Cycle?

Active period	Days	Total KPV	10 mg vials
6 weeks	42	21 mg	3 vials
8 weeks	56	28 mg	3 vials

Does KPV Need to Be Cycled?

Active framework	Reported break	Evidence note
4 weeks	2–4 weeks	Community convention; no trial comparison
6–8 weeks	2–4 weeks	Commonly discussed; no proven reset period
12 weeks	About 4 weeks or longer	Extended community pattern; not clinically established
16 weeks	4–8 weeks	Anecdotal framework with major evidence gaps

Does the KPV Route Change the Cycle Length?

Route	What is discussed	Cycle evidence
Oral	Gut-focused community frameworks and animal PepT1 studies	No established human oral cycle
SubQ	Systemic community protocols	No completed human SubQ dose or cycle trial
Topical	Formulation-specific skin research	No standard concentration or cycle across formulations

Storage and handling

The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.

Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
Cloudy solution, with particles or a color change: discard. There is no recovery.

Lab tests and monitoring

This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.

Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.

Evidence limits

What these numbers are and what they are not. The values above were preserved exactly as they appear in the source, without reinterpretation. What the source describes as community practice is marked as such in the tables; what came from a published trial is too. A dose repeated by many people does not become a validated dose by repetition.

← Back to all compounds